Timothy Obermiller, MD
Pulmonary Disease · Kalispell, MTNPI 1720011927
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.9% of the total across 88 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AstraZeneca at 26.8% of the total. Reporting peaked in 2019 at $1,136 and has fallen 92.8% since, to $82 in 2022.
Across 88 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$406
- Boehringer Ingelheim$194
- Genentech USA, Inc.$124
- Johnson & Johnson$100
- Olympus America Inc.$98
- E.r. Squibb & Sons, L.L.C.$88
- plus $508 from 18 others
Across 12 payments — averaging $23,121 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$229K
- Omeros Corporation$23K
- Takeda Pharmaceuticals U.S.A., Inc.$14K
- Amgen$11K
- Genentech, Inc.$18
What the payments were for
- Food & beverage$1,44095%
- Education$785%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $406 |
| Boehringer Ingelheim | 12 | $194 |
| Genentech USA, Inc. | 5 | $124 |
| Johnson & Johnson | 7 | $100 |
| Olympus America Inc. | 2 | $98 |
| E.r. Squibb & Sons, L.L.C. | 6 | $88 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $76 |
| Grifols USA, LLC | 4 | $61 |
| Mylan Specialty L.p. | 3 | $50 |
| Novartis | 3 | $45 |
| Insmed, Inc. | 3 | $40 |
| Actelion Pharmaceuticals US, Inc. | 2 | $34 |
| Mallinckrodt Enterprises LLC | 2 | $34 |
| Amgen | 2 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| La Jolla Pharmaceutical Company | 1 | $16 |
| United Therapeutics Corporation | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| GSK | 1 | $14 |
| Aegerion Pharmaceuticals, Inc. | 1 | $14 |
| Merck | 1 | $12 |
| Gilead | 1 | $12 |
| Sanofi | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,518 in reported general payments places this provider in the 70th percentile of 43 pulmonary disease providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 26 | $628,490 |
| Tyvaso DpiTreprostinil | 19 | $458,577 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 370 | $290,444 |
| OfevNintedanib Esylate | 18 | $228,655 |
| AdempasRiociguat | 12 | $170,157 |
| Ambrisentan | 58 | $142,398 |
| Pirfenidone | 45 | $109,427 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 113 | $85,597 |
| EliquisApixaban | 75 | $51,074 |
| Dupixent SyringeDupilumab | 13 | $48,356 |
| Breo ElliptaFluticasone/Vilanterol | 77 | $37,410 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 55 | $27,717 |
| Spiriva RespimatTiotropium Bromide | 42 | $25,273 |
| DuleraMometasone/Formoterol | 68 | $23,706 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $21,122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi | $34 | $628,49026 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $14 | $356,435500 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $194 | $281,645115 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $406 | $102,521166 claims |
| MerckDulera | $12 | $23,70668 claims |
| Johnson & JohnsonXarelto | $100 | $13,35013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 43 pulmonary disease providers in Montana.
Other pulmonary disease in Kalispell
- Bethany WeilerKalispell$14K
- Dillon NolandKalispell$6K
- Anthony Dal NogareKalispell$989
- Kevin KeetonKalispell$903
- Sue FesslerKalispell$558
- Brent PistoreseKalispell$288
- Seth ClemensKalispell$228
- Wallace ProphetKalispell$78
- Robert CurtisKalispell$34
- Gregory LemenseBozeman$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.